Circulating resistin levels and risk of multiple myeloma in three prospective cohorts
A partir des données de trois cohortes portant sur 178 patients atteints d'un myélome multiple et sur 358 témoins, cette étude prospective évalue l'association entre les niveaux sériques de résistine, une hormone sécrétée par le tissu adipeux, et le risque de développer la maladie
Background: Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case–control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively. Methods: We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium. Results: In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24–0.83 and 0.54; 95% CI 0.29–0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; Ptrend=0.03). No association was observed for women. Conclusions: This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.